HIV-1 utilizes tRNA Lys,3 as the primer for initiation of reverse transcription. To further examine the tRNA sequence and structural requirements for primer selection, we developed a complementation system which required tRNA Lys to be provided in trans. We constructed an HIV-1 provirus in which the primer-binding site (PBS) was altered to be complementary to the 3′ terminal 18-nucleotides of E. coli tRNA Lys,3 , which shares many bases with mammalian tRNA Lys,3 , and demonstrated that infectious virus was obtained only if the provirus was co-transfected with the plasmid encoding E. coli tRNA Lys,3 . In the current study we have mutated E. coli tRNA Lys,3 so that nucleotides within the stem of the anticodon stem-loop were made identical to mammalian tRNA Lys,3 . Analysis of the complementation revealed that the modified E. coli tRNA Lys,3 (E. coli tRNA Lys,3 -MA) complemented 3-5 times more efficiently than E. coli tRNA Lys,3 . Mutation of nucleotides within the anticodon stem region of E. coli tRNA Lys,3 -MA that differed from E. coli tRNA Lys,3 revealed the importance of the nucleotide sequence for efficient use in reverse transcription. The results of our studies highlight that multiple regions of mammalian tRNA Lys,3 are important for the preference of tRNA Lys,3 as the primer for HIV-1 reverse transcription.
Introduction
Human immunodeficiency type 1 (HIV-1), like most lentiviruses, exclusively selects tRNA Lys,3 as the primer for reverse transcription (Mak et al., 1997; Marquet et al., 1995) . Previous studies from this laboratory and others have shown that HIV-1 has the capacity to select alternative tRNAs as the primers for reverse transcription (Das et al., 1995; Li et al., 1994; Wakefield et al., 1995) . Alteration of the PBS to be complementary to numerous tRNAs allows HIV-1 to utilize these tRNAs for replication. However, the viruses rapidly revert to utilize tRNA Lys,3 as the primer for reverse transcription unless additional mutations are made upstream of the PBS in a region called the A-loop, which is complementary to the anticodon of tRNA Lys, 3 Kang et al., 1997 Wakefield et al., 1996; Zhang et al., 1998) . Additional regions within the HIV-1 genome have also been found to potentially be important in primer selection and reverse transcription. A region (primer activation signal) complementary to the TΨC stem-loop (nucleotides 50-57) of tRNA Lys,3 is located upstream of the PBS in the HIV-1 genome (Beerens et al., 2001) . tRNA Lys,3 also plays a role in the second strand transfer during completion of the minus-strand DNA (Brule et al., 2000) . Interaction between tRNA Lys,3 and U3 during the first strand transfer of HIV reverse transcription is facilitated by complementarity between the U3 and nucleotides within the stem of the tRNA Lys,3 anticodon RNA stem-loop.
To further understand the mechanism of primer selection, it would be advantageous to be able to manipulate the tRNA primer used for reverse transcription. Since it is difficult to effectively manipulate endogenous levels of tRNA in mammalian cells, previous studies from this laboratory have described a complementation system in which an exogenous tRNA, yeast tRNA Phe , was supplied in trans to HIV-1 which had the PBS mutated to be complementary to the 3′ terminal 18-nucleotides of yeast tRNA Phe Morrow, 2003, 2005; Morrow, 2000, 2001) . Expression of yeast tRNA Phe from a cDNA resulted in a tRNA that undergoes aminoacylation, nuclear transport, and inclusion into the host cell protein synthesis cycle (Kelly and Morrow, 2005) . Using a defined set of mutants, we were able to ascertain that transport from the nucleus to the cytoplasm is a key requirement for the tRNA to be selected as a primer for HIV-1 reverse transcription . Since previous studies have suggested that the reason for the preferred selection of tRNA Lys,3 as a primer is due to the incorporation of lysyl-tRNA synthetase into HIV-1 virions, it was important to develop a system which more accurately recapitulated the HIV-1 primer selection process and demonstrated a preference for tRNA Lys,3 (Cen et al., 2002; Javanbakht et al., 2003) . To achieve this goal, we engineered an HIV-1 with a PBS complementary to E. coli tRNA Lys,3 , which maintains many of the similar features of mammalian tRNA Lys,3 (McCulley and Morrow, 2006 ). Using this system, we were able to demonstrate that HIV-1 replication could be comple-mented in trans with E. coli tRNA Lys,3 supplied in the form of a cDNA. Analysis of E. coli tRNA Lys,3 anticodon mutants revealed no correlation between aminoacylation and the ability to complement, indicating that interactions with the lysyl-tRNA synthetase do not fully explain the preferential usage of tRNA Lys,3 as a primer (McCulley and Morrow, 2006) .
The level of complementation observed using E. coli tRNA Lys,3 was lower to that observed for the yeast tRNA Phe system, indicating no preferential use of E. coli tRNA Lys,3 even though this tRNA interacts with lysyl-tRNA synthetase. To further explore this result in the current study, we have mutated the cDNA encoding E. coli tRNA Lys,3 to be identical to mammalian tRNA Lys,3 with the exception of the acceptor stem and the necessary 3′ terminal 18-nucleotides that anneal with the PBS. We have compared the complementation of E. coli tRNA Lys,3 and the modified E. coli tRNA Lys,3 (tRNA Lys,3 -MA). Results of our studies demonstrate that tRNA Lys,3 -MA was approximately 3 to 5-fold more efficient in complementation than E. coli tRNA Lys,3 due to nucleotides within the Fig. 1 . Mammalian tRNA Lys,3 , E. coli tRNA Lys,3 , and E. coli tRNA Lys,3 -MA. (A) The cloverleaf depiction of mammalian tRNA Lys,3 , E. coli tRNA Lys,3 , and E. coli tRNA Lys,3 -MA. The 3′ terminal 18-nucleotides and the anticodon region are outlined in the mammalian tRNA Lys,3 . The boldface nucleotides in the E. coli tRNA Lys,3 represent base variance between mammalian and E. coli tRNA Lys,3 sequence. The A73G mutation is indicated by an arrow. Circled nucleotides in the E. coli tRNA Lys,3 -MA represent nucleotides that have been changed from E. coli tRNA Lys,3 sequence to mammalian tRNA Lys,3 sequence. (B) Aminoacylation of E. coli tRNA Lys,3 , E. coli tRNA Lys,3 -MA, and E. coli tRNA Lys,3 (A73G). Migration of the aminoacylated (AA) and deacylated (DA) samples is shown. Cytoplasmic tRNAs were collected from 293HEK cells that were transfected with pU6Ec Lys , pU6Ec Lys (A73G), and pU6Ec Lys (MA). All cytoplasmic RNA was isolated under acidic conditions. Lanes 1 and 2 were loaded with cytoplasmic RNA from pU6Ec Lys (A73G) transfection; lanes 7 and 8 were loaded with cytoplasmic RNA from mock transfection; lanes 5 and 6 were loaded with cytoplasmic RNA from pU6Ec Lys transfection; lanes 3 and 4 were loaded with cytoplasmic RNA from pU6Ec Lys (MA) transfection. All lanes were probed for E. coli tRNA Lys,3 . DA controls were prepared by pH adjustment (basic) and incubation for 1 h at 42°C. DA samples are shown in lanes 1, 3, 5, and 7. anticodon stem and the variable loop of E. coli tRNA Lys,3 . The results of these studies are discussed with respect to the preferential selection of tRNA Lys,3 as the primer for HIV-1 reverse transcription.
Results
In a previous study, we described the construction and characterization of a complementation system in which E. coli tRNA Lys,3 was provided in trans to an HIV-1 genome in which the PBS was altered to be complementary to the 3′ terminal 18nucleotides of E. coli tRNA Lys,3 (McCulley and Morrow, 2006) . While we demonstrated complementation with respect to production of infectious virus, the level of complementation was not substantially higher than that found for a similar system which utilized yeast tRNA Phe and an HIV-1 proviral genome with the PBS complementary to 3′ terminal 18-nucleotides of yeast tRNA Phe . Thus, we have not recapitulated the enhanced preference of HIV-1 for tRNA Lys, 3 . Comparison of mammalian tRNA Lys,3 with E. coli tRNA Lys,3 revealed considerable changes within the anticodon stem region between the two tRNAs. To determine if alteration of these anticodon stem nucleotides could enhance the capacity of E. coli tRNA Lys,3 to complement the HIV-1 viral genome, we constructed a hybrid E. coli tRNA Lys,3 (E. coli tRNA Lys,3 -MA) that consisted of E. coli tRNA Lys,3 components (acceptor stem, TΨC stem-loop) and mammalian tRNA Lys,3 components (variable loop, anticodon stem-loop, D stem-loop) (Fig. 1A ).
The first step in the characterization of E. coli tRNA Lys,3 -MA was to determine if it undergoes aminoacylation as E. coli tRNA Lys,3 . Following transfection, RNA was isolated under acidic conditions to maintain the integrity of the amino acid-tRNA bond. The samples were analyzed by gel electrophoresis and probed for E. coli tRNA Lys,3 . A deaminoacylated control was obtained by treating a portion of the sample with high pH buffer to break the amino acid-tRNA bond. We created a second E. coli tRNA Lys,3 mutant which contained an A73G mutation so that the last four nucleotides of E. coli tRNA Lys,3 would be identical to the last four nucleotides of mammalian tRNA Lys,3 (Fig. 1A) . The nucleotide at position 73 has also been implicated as a discriminator base (Huang et al., 1996; Shiba et al., 1997) . Analysis of the samples revealed that all tRNAs were predominately aminoacylated following expression in mammalian cells (Fig. 1B) . Slight differences were observed that could be attributed to processing given that the amino acid-tRNA bond is highly heat and pH sensitive. No significant differences were observed in the intracellular expression of the tRNAs using a range of plasmid concentrations (data not shown).
Complementation of HIV genomes containing a PBS complementary to E. coli tRNA Lys,3
We first compared the capacity of E. coli tRNA Lys,3 and E. coli tRNA Lys,3 -MA to complement the HIV-1 proviral genome containing a PBS complementary to E. coli tRNA Lys,3 ( Fig.  2A ). Using a fixed ratio of tRNA plasmids to proviral plasmids, we generated virus and tested it for infectivity. The amount of infectious virus produced is determined following infection of JC53-BL cells, which encode a luciferase gene positioned downstream from an HIV-1 LTR. Following infection, the expression of Tat results in the transcription of luciferase, which is then detected using a standard assay. Previous studies have demonstrated that the amount of luciferase produced in the standard assay correlates with the amount of infectious virus (McCulley and Morrow, 2006; Wei et al., 2002) . In our complementation system, the production of infectious virus was dependent upon the co-transfection of the proviral genome and plasmids encoding E. coli tRNA Lys,3 . Under the standard conditions, the amount of infectious virus produced by cotransfection with E. coli tRNA Lys,3 -MA was approximately 3-5 times to that produced by co-transfection with E. coli tRNA Lys,3 (Fig. 2B ). The amount of virus produced by co-transfection with E. coli tRNA Lys,3 -MA was comparable to that produced by transfection of the HXB2 plasmid which relies on the capture of endogenous mammalian tRNA Lys,3 for infectivity. Using a titration of plasmids encoding E. coli tRNA Lys,3 -MA, we found that the amount of infectious virus produced was greater than that following co-transfection with E. coli tRNA Lys,3 over a wide range of plasmid amounts (Fig. 2C ). The increase in the level of complementation was generally 3-5 times greater for E. coli tRNA Lys,3 -MA compared to E. coli tRNA Lys,3 . A mutant E. coli tRNA Lys,3 with only the A73G mutation alone did not result in increased production of infectious virus (Fig.  2C) . Thus, the A73G mutation, made to correspond to the four terminal nucleotides of mammalian tRNA Lys,3 within the 3′ terminal 18-nucleotides of E. coli tRNA Lys,3 , did not enhance selection and use of E. coli tRNA Lys,3 (A73G).
Importance of nucleotides with an anticodon stem for complementation
The major nucleotide differences between E. coli tRNA Lys -MA and E. coli tRNA Lys,3 reside in the anticodon stem ( Fig.  1A) . Previous studies have shown that the anticodon stem-loop of tRNA Lys,3 imparts unique properties with respect to interaction with codon-anticodon involved in protein synthesis. Given the fact that the A-loop anticodon interaction has been suggested to resemble a codon-anticodon interaction, it is possible that the nucleotides within this stem-loop facilitate this interaction resulting in the enhanced complementation (Puglisi and Puglisi, 1998) . To investigate this possibility, we made a series of mutations in the E. coli tRNA Lys,3 anticodon stem to determine which would result in enhanced complementation. The first mutation substituted a U-A base pair at nucleotides 27-43 that were G-U base pair in E. coli tRNA Lys,3 (Fig. 3A) . This substitution should result in the introduction of a Ψ-A base pair similar to that seen in mammalian tRNA Lys,3 . A second mutation was also introduced in which a C-G and A-U base pair at nucleotides 28-42 and 29-41 would give a complete stem sequence of mammalian tRNA Lys,3 (Fig. 3A) . Analysis of tRNA aminoacylation following transfection revealed that both mutants were aminoacylated similar to that of E. coli tRNA Lys,3 and E. coli tRNA Lys,3 -MA (data not shown). The capacity of these tRNAs to complement the HIV-1 proviral genome with a PBS complementary to E. coli tRNA Lys,3 was determined. Surprisingly, we found no increase in complementation as the nucleotides within the stem were made to correspond to the stem region of E. coli tRNA Lys,3 -MA (Fig. 3B ). These mutants did complement, but at levels similar to that for the unaltered E. coli tRNA Lys,3 . Thus, alteration of the nucleotides within the stem of E. coli tRNA Lys,3 to correspond to that of E. coli tRNA Lys3 -MA did not impart the enhanced complementation observed with E. coli tRNA Lys,3 -MA.
Inspection of E. coli tRNA Lys,3 -MA revealed an additional nucleotide change in the variable loop at nucleotide 44. In E. coli tRNA Lys,3 , this nucleotide is a U while in mammalian tRNA Lys,3 it is a G. To determine the effects of this single nucleotide change, we constructed a mutant E. coli tRNA Lys,3 in which the U was changed to a G (Fig. 4A ). We then characterized the capacity of this tRNA to complement the HIV-1 proviral genome with a PBS complementary to E. coli tRNA Lys,3 . Analysis revealed that complementation was slightly enhanced with the U44G mutation compared to the complementation with a tRNA containing the stem identical to mammalian tRNA Lys,3 , though, the levels of complementation did not reach that for E. coli tRNA Lys,3 -MA (Fig. 4B) .
Collectively, the results of these studies demonstrate that the capacity of E. coli tRNA Lys,3 -MA to complement greater than that observed for E. coli tRNA Lys,3 resides in the continuity of the nucleotides within the variable loop and the stem of the anticodon stem-loop.
Discussion
In the current study, we have utilized an in trans complementation system to ascertain the importance of nucleotides in tRNA Lys,3 for selection and use in HIV-1 reverse transcription. Our experiments relied on the use of E. coli tRNA Lys,3 , which shares many features in common with mammalian tRNA Lys,3 . A major difference resides in the 3′ terminal 18-nucleotides, which interact with the HIV-1 PBS, and the nucleotides within the anticodon stem of the tRNA. Although E. coli tRNA Lys,3 can complement an HIV-1 proviral genome in which the PBS was made complementary to the 3′ terminal 18-nucleotides of this tRNA, we found that the complementation was enhanced if the nucleotides within the variable region and the anticodon stem of E. coli tRNA Lys,3 were made to correspond to that of mammalian tRNA Lys,3 (E. coli tRNA Lys,3 -MA). Analysis of the role of individual nucleotides within the variable region and anticodon stemloop indicated that all changed nucleotides within the variable and anticodon stem-loop were important for the enhanced complementation observed with E. coli tRNA Lys,3 -MA.
Previous studies have suggested that the RNA structures of E. coli tRNA Lys,3 and mammalian tRNA Lys,3 are similar in the anticodon region (Durant et al., 2005; Sprinzl et al., 1991; Sudarsan et al., 2006; Yarian et al., 2000) . Much of this is due to analogous post-transcriptionally modified bases at positions 34 and 37, and a pseudouridine at position 39. Previous studies from our group and others have shown that E. coli tRNA Lys,3 can be aminoacylated by mammalian lysyl-tRNA synthetase (McClain et al., 1990; McCulley and Morrow, 2006; Stello et al., 1999; Tamura et al., 1992) . The major differences between mammalian and E. coli tRNA Lys,3 reside in the nucleotides sequence in the stem of the anticodon stem-loop. Thus, the results of our studies to mutate nucleotides within the stem to correspond to mammalian tRNA Lys,3 were surprising in that they did not result in enhanced complementation by E. coli tRNA Lys,3 . In fact, the only mutation that generated an increase in complementation, albeit not at the level of E. coli tRNA Lys,3 -MA, was a mutation in the variable loop. Our results are consistent with the idea that tRNA Lys,3 sequence UGAGGG is important for tRNA Lys,3 to be effectively selected as the primer for initiation of reverse transcription. Interestingly, this sequence is involved in at least two interactions with the HIV-1 genome (Fig. 5A) . In the first, this sequence forms an intermolecular interaction with the U5 region of the HIV-1 viral genome within the tRNA U5 initiation complex (Isel et al., 1993 (Isel et al., , 1996 . To address this issue, we made additional mutations in the HIV-1 proviral genome to compensate for mismatched base pairs as a result of interaction with E. coli tRNA Lys,3 (Fig. 5B ). However, the complementation observed for this virus with E. coli tRNA Lys,3 was not greater than that found for E. coli tRNA Lys,3 -MA with the wild-type virus, suggesting that this interaction could not account for the enhanced complementation observed in our study (data not shown). Thus, we do not believe that the lower complementation of E. coli tRNA Lys,3 compared to tRNA Lys,3 -MA was due to the inability to interact with the U5 region. It is possible though that the extensive refolding of tRNA Lys,3 required to form the complex between tRNA:viral genome could have been affected by the nucleotide differences between E. coli tRNA Lys,3 and tRNA Lys,3 -MA. Additional studies will be required to test this possibility.
A second interaction between tRNA Lys,3 and the viral genome has been shown from in vitro studies where complementarity between the nucleotides in the anticodon stem, part of the variable loop of tRNA Lys,3 , and the U3 facilitated the first strand transfer of HIV-1 reverse transcription (Brule et al., 2000) . In this in vitro system, a several fold enhancement of the strand transfer was observed using an in vitro synthesized tRNA that had regions complementary to the regions in U3. Interestingly, the nucleotides within the U3 are highly conserved among all other lentiviruses. There are several nucleotide mismatches between the E. coli tRNA Lys,3 and the U3 sequence that might reduce the efficiency of strand transfer and hence the production of infectious virus (Fig. 5C ). Alteration of the sequence to correspond to tRNA Lys,3 -MA provides complete sequence complementarity with the U3 region. However, it is not clear whether this interaction between these specific nucleotides in U3 and tRNA Lys,3 is absolutely required. For example, previous studies from this laboratory have identified several tRNAs that can be stably utilized by HIV if A-loop PBS modifications were made (Wakefield et al., 1996; Zhang et al., 1998) . One of these viruses, which was engineered Fig. 5 . Mammalian tRNA Lys,3 and the corresponding potential interactions with the proviral U3 region. (A) The cloverleaf depiction of mammalian tRNA Lys,3 with outlined anti-PBS region, which interacts with the PBS in the viral RNA genome, anti-U3 region, which interacts with the U3 region in the viral RNA genome, and anti-A-loop region, which interacts with the A-rich loop in the viral RNA genome during reverse transcription. (B) Proposed interactions between HIV-1 (HXB2) and E. coli tRNA Lys,3 based on Isel structure (Isel et al., 1993 (Isel et al., , 1996 . Boxed bases represent E. coli tRNA Lys,3 . Bolded nucleotides AAUU in E. coli tRNA Lys,3 proposed to interact with HIV-1 genome in Isel structure; the circled nucleotides in HIV-1 genome were changed to promote Isel structure with E. coli tRNA Lys,3 . However, HIV-1 genomes with these changes did not show enhanced complementation with E. coli tRNA Lys,3 (data not shown). The bold D in tRNA Lys,3 is in the D loop. (C) Schematic of viral RNA anticodon tRNA Lys,3 interaction in the U3 region. The sequence fragment of the viral U3 RNA genome that base pairs with the stem and part of the variable sequence found in the tRNA Lys,3 . All nucleotides in mammalian tRNA Lys,3 and E. coli tRNA Lys,3 -MA are complementary to the viral U3 RNA genome sequence, whereas only 5 out of 9 nucleotides are complementary in E. coli tRNA Lys, 3 . to utilize tRNA His requires an additional change within the Aloop to stably utilize this tRNA for reverse transcription. Brule et al. found that a similar region within the viral RNA genome in U3 is complementary to the sequences within tRNA His , but was not the same required for the interaction between U3 and tRNA Lys,3 (Brule et al., 2000) . Thus, HIV-1 that has been forced to utilize tRNA His by mutations within the PBS and A-loop region might have evolved to alter nucleotides within U3 to facilitate the first strand jump. Additional experiments will be required to delineate the interaction between U3 and tRNA Lys,3 during reverse transcription.
Collectively, the results of these studies demonstrate a dynamic relationship between the HIV-1 viral genome and the host during acquisition of the primer utilized for virus replication. The results of our studies are consistent with the concept that HIV-1 has evolved to efficiently select and use tRNA Lys,3 as the preferred primer through in part maximization of tRNA:genome RNA interactions. To date, the 3′ terminal 18nucleotides, TΨC loop, and anticodon stem-loop region of tRNA Lys, 3 have been shown to be involved with the interaction (Fig. 5A ). Further studies using this unique in trans complementation system will allow elucidation of the interactions between the tRNA Lys,3 and the viral genome required for the preferential selection of tRNA Lys,3 .
Materials and methods

Tissue culture
The 293HEK and JC53-BL cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic (Gibco/BRL, Gaithersburg, MD.). Cell cultures were maintained in 37°C incubator supplemented with 5% CO 2 .
Proviral and tRNA plasmids
The proviral plasmid encoding the full length HXB2 with a PBS altered to be complementary to the 3′-terminal 18nucleotides of E. coli tRNA Lys,3 and the E. coli tRNA Lys gene was constructed previously (McCulley and Morrow, 2006) . The E. coli tRNA Lys,3 (A73G), E. coli tRNA Lys,3 (MA), E. coli tRNA Lys,3 (PsiCA), E. coli tRNA Lys,3 (Psi), and E. coli tRNA Lys,3 (G) were prepared by PCR extension with the use of the following primers: (forward A73G) GCAGGGCTCG-AGGTCCGGGTCGTTAGCTCAGTTGGTAGAGCAGTT-GACTTTTAATCAATTGGTCGCAGG3′, (reverse A73G) GCGGACGAAGCTTCCAAAAAACGGGTCGTGCAG-GACTTGAACCTGCGACCAATTGATTAAAAGTCAA3′; (forward MA) 5′GCAGGGCTCGAGGTCCGGGTCGT-TAGCTCAGTCGGTAGAGCATCAGACTTTTAATCT-GAGGGTCGCAGG3′, (reverse MA) 5′GCGGACGAAGC-TTCCAAAAAATGGGTCGTGCAGGACTTGAACCTGC-GACCCTCAGATTAAAAGTCTG3′; (forward PsiCA) 5′ GCAGGGCTCGAGGTCCGGGTCGTTAGCTCAGTTGG-TAGAGCATCAGACTTTTAATCTGATGGTCGCAGG3′, (reverse PsiCA) 5′GCGGACGAAGCTTCCAAAAAATGGG-
The PCR products were TA cloned into pGEM T-Easy vector (Promega, Madison, WI), and the resultant TA clones were digested using XhoI and HindIII restriction enzymes in order to release the E. coli tRNA Lys constructs (approximately 100-bp). Subsequently, the E. coli tRNA Lys constructs were ligated into an LS9 plasmid upstream of a polymerase III promoter using the XhoI and HindIII restriction sites Morrow, 2003, 2005; . The end products resulted in plasmids labeled pU6Ec Lys (A73G), pU6Ec Lys (MA), pU6Ec Lys (PsiCA), pU6Ec Lys (Psi), and pU6Ec Lys (U43G). All plasmids were screened with enzyme restriction and verified by DNA sequencing.
Co-transfections
Complementation of HIV-1 proviral mutants was performed in a previously described manner (McCulley and Morrow, 2006) . Briefly, 293HEK cells were co-transfected with tRNAcarrying plasmids and HIV-1 proviral mutants 24 h after seeding in 6-well plates. Transfections were achieved using a calcium-phosphate method previously described (Jordan et al., 1996) . The cells were co-transfected with 500 ng of proviral plasmid and 100 ng, 500 ng, 1000 ng, and 1500 ng of tRNAcarrying plasmid. Mock and control (proviral plasmids alone, or tRNA plasmids alone) transfections were also included. Approximately 7 h after co-transfection, the cells were washed once with 1× PBS and replenished with fresh media. Approximately 48 h post-transfection, supernatants were collected, centrifuged at 3000×g, and serially diluted for infection of JC53-BL cells.
JC53-BL Infections
Supernatants collected from co-transfections were used in JC53-BL reporter assay in order to determine infectious viral units from luciferase activity (Wei et al., 2002) . JC53-BL assay was performed as described previously (McCulley and Morrow, 2006) . Briefly, supernatants were diluted 1:3 in DMEM supplemented with 2% FBS, followed by two sequential 1:5 dilutions, and used to infect JC53-BL cells that were seeded 24 h pre-infection. JC53-BL cells with the added supernatants were incubated for 2 h in a 37°C incubator supplemented with 5% CO 2 . After 2 h, DMEM supplemented with 10% FBS was added to each well and the cells were incubated for additional 48 h. To determine luciferase activity, cells were lysed using M-PER Mammalian Protein Extraction Reagent (PIERCE, Rockford, IL) and approximately 20 μL of each sample was transferred to a microplate. Reporter Lysis Buffer (Promega, Madison, WI) was added to each sample in the microplate and the light intensity was measured using a Tropix TR717 Microplate Luminometer (Applied Biosystems, Foster City, CA). Wells that contained lysed samples from uninfected cells represented background and the luciferase activity obtained from these wells was subtracted from all other samples. Luciferase activity for pHXB2(EcPBS Lys ), without the complementing tRNA, was set as background also. The difference obtained from subtracting luciferase activity values of uninfected samples from luciferase activity values of pHXB2 (EcPBS Lys ), without the complementing tRNA, was subtracted from all complementation samples. The luciferase activity values of two dilutions per sample were averaged. Relative Light Units (rLU) per mL were calculated by dividing the luciferase activity values by their corresponding dilutions.
RNA isolation and tRNA analysis
293HEK cells were transfected with pU6Ec Lys , pU6Ec Lys (A73G), pU6Ec Lys (MA), pU6Ec Lys (PsiCA), pU6Ec Lys (Psi), and pU6Ec Lys (U43G) using calcium phosphate via a previously described method (Jordan et al., 1996) . Aminoacyl tRNAs were collected approximately 48 h post-transfection. Collection and isolation of aminoacylated tRNAs were performed as previously described Morrow, 2003, 2005; McCulley and Morrow, 2006) . Aminoacyl tRNAs were also isolated from mock-transfected 293HEK cells. All E. coli tRNA Lys molecules were detected using a [γ-32 P] ATP kinased oligo, 5′GGTCGTGCAGGATTCGAACCTGCGACCAA3′, that was labeled with the use of Ready-to-go T4 polynucleotide kinase (Amersham Pharmacia Biotech, Piscataway, NJ). Aminoacyl tRNAs were separated based on charge using an acidic polyacrylamide gel and analyzed using Northern blotting Morrow, 2003, 2005; McCulley and Morrow, 2006 ). X-ray film was exposed to the probed membranes and developed using the SRX-101A developer (Konica, Wayne, NJ).
